LISA, Francesco
LISA, Francesco
SCIENZE MEDICHE
Biological prognostic factors in advanced metastatic melanoma patients treated with chemoimmunotheraphy.
1997-01-01 Fierro MT; Quaglino P; Lisa F; Savoia P; Bernengo MG
KM-93 expression on peripheral blood lymphocytes (PBL) in inflammatory skin diseases, mycosis fungoides and Sézary syndrome.
1995-01-01 Quaglino P; Fierro MT; Savoia P; Novelli M; Lisa F; Bernengo MG
Low-dose intermittent Alemtuzumab in Sézary Syndrome: clinical activity, toxicity profile and immunological findings in 17 patients.
2008-01-01 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
Macrophage-mediated antitumor immunostimulation or immunosuppression modulates IL-2 therapeutic efficacy in advanced metastatic melanoma (MM) patients.
1997-01-01 Quaglino P; Lisa F; Cappello N; Zaccagna A; Bernengo MG.
PAS expression is related to survival in Sézary syndrome patients
2008-01-01 Novelli Mauro; La Selva Roberta; Quaglino Pietro; Ponti Renata; Comessatti Alessandra; De Matteis Antonietta; Titli Stefano; Lisa Francesco; Fierro Maria Teresa; Bernengo Maria Grazia
Prognostic factors in Sezary sindrome
1997-01-01 Bernengo MG; Quaglino P; Novelli M; Cappello N; Doveil GC; Lisa F; De Matteis A; Fierro MT; Appino A.
Significato prognostico dei livelli sierici di interleuchina-12 endogena in pazienti affetti da melanoma metastatico in fase avanzata trattati con chemioterapia o chemioimmunoterapia.
2002-01-01 Quaglino P; Osella-Abate S; Comessatti A; Lisa F; Bernengo MG
Skin infiltrating lymphocyte flow-cytometric immunophenotyping: automated mechanical biopsy disaggregation and CD45 gating.
1996-01-01 Novelli M; Fierro MT; Lisa F; De Matteis A; Quaglino P; Savoia P; Verrone A; Cambieri I; Bernengo MG